MA37954A1 - Méthode d'administration d'un agent hypnotique/sédatif - Google Patents

Méthode d'administration d'un agent hypnotique/sédatif

Info

Publication number
MA37954A1
MA37954A1 MA37954A MA37954A MA37954A1 MA 37954 A1 MA37954 A1 MA 37954A1 MA 37954 A MA37954 A MA 37954A MA 37954 A MA37954 A MA 37954A MA 37954 A1 MA37954 A1 MA 37954A1
Authority
MA
Morocco
Prior art keywords
hypnotic
administering
sedative agent
agent
methyl
Prior art date
Application number
MA37954A
Other languages
English (en)
Inventor
Maki Kondo
Toshihiko Konomi
Shigehito Sato
Matsuyuki Doi
Original Assignee
Paion Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Paion Uk Ltd filed Critical Paion Uk Ltd
Publication of MA37954A1 publication Critical patent/MA37954A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Anesthesiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Cette invention concerne un agent hypnotique/sédatif comprenant du propanoate de méthyl 3-[(4s)-8-bromo-1-méthyl-6-(2-pyridinyl)-4h-imidazo[1,2-a][1,4]benzodiazépine-4-yle] ou son sel, ledit agent étant injecté à un patient par voie veineuse en deux phases et permettant d'induire une anesthésie générale rapidement et en toute sécurité, et de maintenir cet état d'anesthésie générale.
MA37954A 2012-08-31 2013-08-30 Méthode d'administration d'un agent hypnotique/sédatif MA37954A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012192081 2012-08-31
PCT/JP2013/073414 WO2014034890A1 (fr) 2012-08-31 2013-08-30 Méthode d'administration d'un agent hypnotique/sédatif

Publications (1)

Publication Number Publication Date
MA37954A1 true MA37954A1 (fr) 2018-07-31

Family

ID=50183693

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37954A MA37954A1 (fr) 2012-08-31 2013-08-30 Méthode d'administration d'un agent hypnotique/sédatif

Country Status (34)

Country Link
US (2) US20150224114A1 (fr)
EP (1) EP2891494B1 (fr)
JP (1) JP6199869B2 (fr)
KR (1) KR102228598B1 (fr)
CN (1) CN104768557A (fr)
AP (1) AP2015008287A0 (fr)
AU (1) AU2013309860B2 (fr)
BR (1) BR112015004477A8 (fr)
CA (1) CA2883667A1 (fr)
CL (1) CL2015000494A1 (fr)
DK (1) DK2891494T3 (fr)
EA (1) EA027370B1 (fr)
ES (1) ES2959499T3 (fr)
FI (1) FI2891494T3 (fr)
GE (1) GEP201706755B (fr)
HK (1) HK1210588A1 (fr)
HR (1) HRP20231302T1 (fr)
HU (1) HUE063967T2 (fr)
IL (1) IL237373B (fr)
LT (1) LT2891494T (fr)
MA (1) MA37954A1 (fr)
MX (1) MX2015002467A (fr)
MY (1) MY171592A (fr)
NZ (1) NZ705177A (fr)
PE (1) PE20151374A1 (fr)
PH (1) PH12015500381B1 (fr)
PL (1) PL2891494T3 (fr)
PT (1) PT2891494T (fr)
SG (1) SG11201501358SA (fr)
SI (1) SI2891494T1 (fr)
TN (1) TN2015000067A1 (fr)
UA (1) UA116452C2 (fr)
WO (1) WO2014034890A1 (fr)
ZA (1) ZA201501207B (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170091770A (ko) 2006-07-10 2017-08-09 파이온 유케이 리미티드 속효형 벤조디아제핀 염 및 이의 중합체 형태
EP2305647A1 (fr) 2009-09-18 2011-04-06 PAION UK Limited Procédé de préparation d'ester de méthyle d'acide 3-[(4S)-8-bromo-1-méthyl-6-(2-pyridinyl)-4H-imidazo[1,2-a][1,4]benzodiazépine-4-yl] propionique ou son sulfonate de benzène, et composants utiles dans ce procédé
EP2450039A1 (fr) 2010-11-08 2012-05-09 PAION UK Ltd. Régime de dosage permettant la sédation avec CNS 7056 (Remimazolam)
AR094963A1 (es) 2013-03-04 2015-09-09 Ono Pharmaceutical Co Reacción de oxidación excelente en el índice de conversión
PL3162804T3 (pl) * 2014-07-23 2020-04-30 Jiangsu Nhwaluokang Pharmaceutical Research And Development Co., Ltd. Nowa pochodna benzodiazepiny i jej zastosowanie
CN105130996B (zh) * 2015-08-07 2017-05-03 成都倍特药业有限公司 苯并二氮杂*衍生物的1,5‑萘二磺酸盐及晶型和它们的制备方法
CN107266452A (zh) * 2016-04-08 2017-10-20 四川科伦药物研究院有限公司 苯并二氮杂*衍生物的盐及其晶体形式、制备方法和用途
AU2017248683A1 (en) * 2016-04-14 2018-10-25 Paion Uk Limited Orally inhaled and nasal benzodiazepines
CN108503644B (zh) * 2016-12-09 2019-06-14 成都倍特药业有限公司 一种苯并二氮杂*衍生物的氢溴酸盐及其制备方法和用途
CN108033964B (zh) * 2017-12-28 2021-02-09 杭州奥默医药股份有限公司 一种吡啶基咪唑并苯并二氮杂卓丙酸酯化合物及其合成和应用
EP3714884A1 (fr) 2019-03-27 2020-09-30 Paion UK Limited Utilisations médicales pour benzodiazépines dotées d'un motif eeg particulier
CN114478535B (zh) * 2020-10-23 2024-02-09 成都苑东生物制药股份有限公司 一种苯磺酸瑞马唑仑ii晶型的制备方法
JP2022108079A (ja) * 2021-01-12 2022-07-25 日本光電工業株式会社 生体情報処理装置、生体情報処理方法、プログラム及び記憶媒体
CN114588164B (zh) * 2022-04-19 2023-08-11 天津医科大学总医院 瑞马唑仑在预防围术期低体温和寒战中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9911152D0 (en) 1999-05-14 1999-07-14 Glaxo Group Ltd Short-acting benzodiazepines
KR20170091770A (ko) 2006-07-10 2017-08-09 파이온 유케이 리미티드 속효형 벤조디아제핀 염 및 이의 중합체 형태
GB0613693D0 (en) 2006-07-10 2006-08-16 Cenes Ltd Benzodiazepine salts (3)
EP2305647A1 (fr) 2009-09-18 2011-04-06 PAION UK Limited Procédé de préparation d'ester de méthyle d'acide 3-[(4S)-8-bromo-1-méthyl-6-(2-pyridinyl)-4H-imidazo[1,2-a][1,4]benzodiazépine-4-yl] propionique ou son sulfonate de benzène, et composants utiles dans ce procédé
EP2450039A1 (fr) * 2010-11-08 2012-05-09 PAION UK Ltd. Régime de dosage permettant la sédation avec CNS 7056 (Remimazolam)

Also Published As

Publication number Publication date
HK1210588A1 (en) 2016-04-29
IL237373B (en) 2020-05-31
SG11201501358SA (en) 2015-04-29
PH12015500381A1 (en) 2015-04-20
HRP20231302T1 (hr) 2024-02-02
EP2891494B1 (fr) 2023-07-19
ES2959499T3 (es) 2024-02-26
MY171592A (en) 2019-10-21
EP2891494A1 (fr) 2015-07-08
WO2014034890A1 (fr) 2014-03-06
TN2015000067A1 (en) 2016-06-29
PL2891494T3 (pl) 2024-01-03
KR20150047573A (ko) 2015-05-04
CA2883667A1 (fr) 2014-03-06
AU2013309860A1 (en) 2015-03-19
BR112015004477A2 (pt) 2017-07-04
PT2891494T (pt) 2023-10-25
UA116452C2 (uk) 2018-03-26
JP6199869B2 (ja) 2017-09-20
ZA201501207B (en) 2019-11-27
US20220152045A1 (en) 2022-05-19
MX2015002467A (es) 2015-11-09
LT2891494T (lt) 2023-11-10
US20150224114A1 (en) 2015-08-13
FI2891494T3 (fi) 2023-10-16
NZ705177A (en) 2018-01-26
PH12015500381B1 (en) 2015-04-20
EA201590467A1 (ru) 2015-07-30
AU2013309860B2 (en) 2017-12-21
KR102228598B1 (ko) 2021-03-15
BR112015004477A8 (pt) 2019-08-27
SI2891494T1 (sl) 2023-12-29
CN104768557A (zh) 2015-07-08
GEP201706755B (en) 2017-10-25
DK2891494T3 (da) 2023-10-23
IL237373A0 (en) 2015-04-30
EA027370B1 (ru) 2017-07-31
AP2015008287A0 (en) 2015-02-28
PE20151374A1 (es) 2015-09-25
CL2015000494A1 (es) 2015-10-02
HUE063967T2 (hu) 2024-02-28
JPWO2014034890A1 (ja) 2016-08-08
EP2891494A4 (fr) 2016-04-27

Similar Documents

Publication Publication Date Title
MA37954A1 (fr) Méthode d'administration d'un agent hypnotique/sédatif
AU2017272293B2 (en) Providing a pharmacokinetic drug dosing regimen
EA201591656A1 (ru) Комбинированная терапия с ибрутинибом
NZ703940A (en) Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
MX2014004960A (es) Composiciones liposomales combinadas para terapia contra el cancer.
IN2014DN09678A (fr)
AU2016204185A1 (en) Methods of administering beta7 integrin antagonists
EP3019130A4 (fr) Kit de libération transdermique prolongée d'un médicament utilisant des compositions liquides ou semi-solides et son procédé d'utilisation
Ota Panitumumab/regorafenib
Vriens Skin toxicity: case report
Kuloglu Alopecia: case report
EA202190596A3 (ru) Предоставление фармакокинетической схемы дозирования лекарственного средства
Teke Blue lunula in an elderly patient: case report
WO2012118833A3 (fr) Identification de la molécule du complément c3 au site de lésion des vaisseaux sanguins dans la rétine d'animaux exposés à l'oxygène
MA20150351A1 (fr) Systèmes et procédés de traitement d'une réponse pharmacodynamique indésirable induite par un opioïde
IN2014DE00648A (fr)